Ueno, Makoto
Ikeda, Masafumi http://orcid.org/0000-0002-4050-2086
Sasaki, Takashi
Nagashima, Fumio
Mizuno, Nobumasa
Shimizu, Satoshi
Ikezawa, Hiroki
Hayata, Nozomi
Nakajima, Ryo
Morizane, Chigusa
Funding for this research was provided by:
Eisai Inc.
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc.
Article History
Received: 4 June 2020
Accepted: 31 August 2020
First Online: 16 November 2020
Ethics approval and consent to participate
: This study was approved by the Institutional Review Board of the National Cancer Center at 5–1-1, Tsukiji, Chuo-ku, Tokyo, 104–0045, Japan (serial number: T4234). All patients provided written informed consent. This study was conducted in accordance with the World Medical Association Declaration of Helsinki, Good Clinical Practices, and local ethical/legal requirements.
: Not applicable.
: Makoto Ueno: reports honoraria from Taiho Pharmaceutical, Yakult Honsha, AstraZeneca, Novartis, Lilly, Teijin Pharma, Shire, Ono Pharmaceutical, and Merck Serono; consulting or advisory role for Shire; research funding from Taiho Pharmaceutical, Shire, Daiichi Sankyo, Eisai, AstraZeneca, Ono Pharmaceutical, MSD, Merck Serono, NanoCarrier, Dainippon Sumitomo Pharma, Incyte, ASLAN Pharmaceuticals, and Yakult Honsha.Masafumi Ikeda: reports honoraria from Abbott, Bayer, Bristol Myers Squibb, Dainippon Sumitomo Pharma, Eisai, Eli Lilly, Nobelpharma, Novartis, Otsuka, Taiho Pharmaceutical, Teijin Pharma, and Yakult Honsha; consulting or advisory role for Bayer, Daiichi Sankyo, Eisai, Kyowa Hakko Kirin, MSD, NanoCarrier, Novartis, Shire, Teijin Pharma, and Eli Lilly; research funding from ASLAN Pharmaceuticals, AstraZeneca, Baxalta/Shire, Bayer, Bristol Myers Squibb, Chugai Pharma, Eisai, Kowa, Kyowa Hakko Kirin, Lilly, Merck Serono, MSD, NanoCarrier, Novartis, Ono Pharmaceutical, Taiho Pharmaceutical, Takara Bio, and Yakult Honsha.Takashi Sasaki: reports honoraria from Taiho Pharmaceutical and Eisai.Fumio Nagashima: reports honoraria from ASKA pharma, Chugai Pharma, Hisamitsu, Kyowa Hakko Kirin, Merck Serono, Mochida, Ono Pharmaceutical, Shionogi, Taiho Pharmaceutical, Takeda, and Yakult Honsha; research funding from AstraZeneca, Baxalta, Bayer, Chugai Pharma, Daiichi Sankyo, Dainippon Sumitomo Pharma, Eisai, Eli Lilly, J Pharma, Kyowa Hakko Kirin, Merck Serono, MSD, NanoCarrier, Mochida, Ono Pharmaceutical, Pfizer, Sanofi, Takeda, Yakult Honsha, and Zeria Pharma.Nobumasa Mizuno: reports grants from Eisai, Merck Serono, AstraZeneca, Zeria Pharma, NanoCarrier, MSD, Dainippon Sumitomo Pharma, Novartis, ASLAN Pharmaceuticals, Incyte, Yakult Honsha, Pharma Valley Center, and Taiho Pharmaceutical; personal fees from Novartis, Yakult Honsha, Ono Pharmaceutical, OncoTherapy Science, Inc., Kyowa Hakko Kirin, Pfizer, Teijin Pharma and Taiho Pharmaceutical; non-financial support from Novartis, Yakult Honsha, Pfizer, and Bristol Myers Squibb.Satoshi Shimizu: reports research funding from NanoCarrier, Eisai, Baxalta, Taiho Pharmaceutical, Dainippon Sumitomo Pharma, AstraZeneca, IQVIA services Japan K.K., and Incyte.Hiroki Ikezawa: is an employee of Eisai Co., Ltd.Nozomi Hayata: is an employee of Eisai Co., Ltd.Ryo Nakajima: is an employee of Eisai Inc.Chigusa Morizane: reports honoraria from Taiho Pharmaceutical, MSD, Novartis, Teijin Pharma, Yakult Honsha, and Ono Pharmaceutical; consulting or advisory role for AstraZeneca, Taiho Pharmaceutical, Ono Pharmaceutical, MSD, Yakult Honsha, AbbVie, and Novartis; research funding from Eisai, Yakult Honsha, Ono Pharmaceutical, Taiho Pharmaceutical, J Pharma, Pfizer, AstraZeneca, and Merck Biopharma.